Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

4 competitors in Achondroplasia

Drug Information

Target Indication

Achondroplasia

Clinical Trial

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

BMRN

BioMarin Pharmaceutical Inc.

Related Pipeline

Phenylketonurias

Pain, Post-operative

Mucopolysaccharidosis IV A

Anemia Associated With End Stage Renal Disease

Hemophilia A With Inhibitor